SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Medical Oncology Referral — Edward W. Brooke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEdward W. Brooke
Date of birth1919-10-26
IdentifiersMRN HR-ML014-SYN-TD; SSN (made up) 000-14-5063
Document date2003-01-13
AuthorHoward Bellamy, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Man of 83 with stage IIA, hormone receptor-positive, HER2-negative right breast cancer, fourteen weeks after bilateral mastectomy and right axillary dissection, on tamoxifen for eleven weeks, started at another hospital. Please take over his adjuvant endocrine therapy, confirm the adjuvant plan, and arrange germline genetic testing. [S]

Urgency: Routine, within four weeks. [S]

Questions for the consultant:

History of Present Illness

He noticed discomfort in the right breast and at first put it down to aging or a strained muscle; he had never had a chest examination by a doctor. Mammography and ultrasound of both breasts showed a 1.9 cm right retroareolar mass and an abnormal right axillary node; the left breast and axilla were normal. Core biopsy: invasive ductal carcinoma, grade 2, ER 95 percent, PR 80 percent, HER2 1+, Ki-67 15 percent, with a positive node. Bilateral mastectomy and right axillary dissection: 1.8 cm tumor, margins clear, 1 of 14 nodes involved (4 mm, no extranodal extension), pT1c pN1a. No chemotherapy or radiation was given. Tamoxifen 20 mg daily since four weeks after surgery, with mild hot flashes. No germline testing yet. No history of blood clots, stroke, or liver disease. Never smoker; no alcohol. Hemoglobin 13.8 g/dL, platelets 214, eGFR 71, liver tests normal, 25-hydroxyvitamin D 24 ng/mL. PHQ-9 score 3. DXA booked. No family history is recorded [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years)One tablet once dailyOral route2002-10-28activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast canceractiveconfirmed C50.121S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D).
Estrogen receptor-positive status of the breast canceractiveconfirmed Z17.0S — Synthetic receptor result; his tumor biology was not made public.
Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health reviewactiveconfirmed Z79.810S — Synthetic adjuvant therapy in the modern episode.
Absence of both breasts after bilateral mastectomyactiveconfirmed Z90.13S — The double mastectomy is reported publicly (D); the coding is synthetic.

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
September 2002Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor beforeD (CLM-0003)
2002Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spreadD (CLM-0004, CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Social History

Vital Signs

DateMeasureValueUnitProvenance
2003-01-13Body height183cmS
2003-01-13Body weight81.6kgS
2003-01-13Body mass index (BMI) [Ratio]24.4kg/m2S
2003-01-13Systolic blood pressure134mm[Hg]S
2003-01-13Diastolic blood pressure76mm[Hg]S
2003-01-13Heart rate70/minS
2003-01-13Respiratory rate14/minS
2003-01-13Body temperature36.6CelS
2003-01-13Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2003-01-13Hemoglobin [Mass/volume] in Blood13.8g/dL13.2-16.6 g/dLNormalS
2003-01-13Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2003-01-13Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2003-01-13Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2003-01-13Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2003-01-13Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
2003-01-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M71mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2003-01-13Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
2003-01-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-55 U/LNormalS
2003-01-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
2003-01-13Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma76U/L40-129 U/LNormalS
2003-01-13Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2003-01-13Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2003-01-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mL30-100 ng/mLLowS
2003-01-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Assessment

Plan of Treatment